Currently, a variety of CD40-targeting agonist monoclonal antibodies are in phase 1 in clinical trials, including CDX-1140 and CDX-301 [110] for the treatment of advanced malignant tumors and solid tumors (Table 1). This evidence concerns the gene CD40 and cancer.